Abstract
IL-17 inhibitors, including secukinumab, brodalumab, and ixekizumab, have been U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis. In addition to psoriasis, IL-17 has been implicated in the pathophysiology of other inflammatory skin conditions. This review aims to synthesize and interpret the literature evaluating the off-label dermatologic uses of IL-17 inhibitors. We performed searches in PubMed and ClinicalTrials.gov for clinical trials, observational studies, case series, and case reports evaluating non-psoriatic uses of the three IL-17 inhibitors. Studies evaluated the efficacy of IL-17 inhibitors for the following conditions: hidradenitis suppurativa (HS), pityriasis rubra pilaris (PRP), Behçet’s disease, alopecia areata, and allergic contact dermatitis. Based on the available literature, secukinumab appears to be a potential treatment for HS, PRP, and Behçet’s disease, while ixekizumab appears to be a potential treatment for HS and PRP. However, more clinical trials data are needed to adequately assess the safety and efficacy of IL-17 inhibitors for the treatment of these conditions.
Original language | English |
---|---|
Pages (from-to) | 41-47 |
Number of pages | 7 |
Journal | Journal of Dermatological Treatment |
Volume | 33 |
Issue number | 1 |
DOIs | |
State | Published - 2022 |
ASJC Scopus Subject Areas
- Dermatology
Keywords
- Behçet’s disease
- IL-17
- Secukinumab
- acne inversa
- alopecia areata
- atopic dermatitis
- brodalumab
- bullous pemphigoid
- contact dermatitis
- hidradenitis suppurativa
- interleukin 17
- ixekizumab
- lupus erythematosus
- pityriasis rubra pilaris
- pyoderma gangrenosum